H.C. Wainwright analyst Edward White lowered the firm’s price target on Nyxoah (NYXH) to $15 from $17 and keeps a Buy rating on the shares after the company announced that the FDA has issued an Approvable Letter regarding the Pre-Market Approval application for the Genio system to treat moderate-to-severe obstructive sleep apnea. The firm now expect a U.S. commercial launch of Genio to be delayed by six months into early 2026 following the news, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue